Biologics in alopecia areata: promise, paradox, and the precision medicine frontier. (PubMed, Expert Opin Biol Ther) - Oct 23, 2026 - "A phase 2a randomized trial of dupilumab showed modest efficacy, most pronounced in patients with elevated baseline IgE...Given the higher bar set by JAK inhibitors and the risk of paradoxical disease, currently available cytokine-targeting biologics cannot be recommended for AA outside of clinical trials. Endotype-stratified investigation represents the most promising path toward precision immunotherapy in AA."
Journal • Review • Alopecia • Immunology • Oncology • IL17A • IL23A • IL4R • TNFA
|
|
Chengxin Li; Jintong Wu; Rui Wang; Zijie Tang
|